Androgen receptor polymorphisms and the incidence of prostate cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 11, Issue 10 I, 2002, Pages 1033-1040

  Chen, Chu ^a   Lamharzi, Najib ^a   Weiss, Noel S ^a   Etzioni, Ruth ^a   Dightman, Douglas A ^a   Barnett, Matt ^a   DiTommaso, Dante ^a   Goodman, Gary ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; BETA CAROTENE; PLACEBO; RETINOL;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA POLYMORPHISM; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXON; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; TANDEM REPEAT;

AGED; CASE-CONTROL STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; RISK FACTORS; TRINUCLEOTIDE REPEATS;

EID: 0036801364     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. Cunha, G. R., Donjacour, A. A., Cooke, P. S., Mee, S., Bigsby, R. M., Higgins, S. J., and Sugimura, Y. The endocrinology and developmental biology of the prostate. Endocr. Rev., 8: 338-362, 1987.
2. Deamaley, D. P. Cancer of the prostate. [Erratum appears in BMJ 308: 975, 1994]. BMJ, 308: 780-784, 1994.
3. Noble, R. L. The development of prostatic adenocarcinoma in Nb rats following prolonged sex hormone administration. Cancer Res., 37: 1929-1933, 1977.
4. Pollard, M., Luckert, P. H., and Schmidt, M. A. Induction of prostate adenocarcinomas in Lobund Wistar rats by testosterone. Prostate, 3: 563-568, 1982.
5. Huggins, C., and Hodges, C. V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res., 1: 293-297, 1941.
6. Huggins, C., Stevens, R. E., Jr., and Hodges, C. V. Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg., 43: 209-223, 1941.
7. Huggins, C., Scott, W. W., and Hodges, C. V. Studies on prostatic cancer. III. The effects of fever, of deoxycorticosterone and of estrogen on clinical patients with metastatic carcinoma of the prostate. J. Urol., 46: 997-1006, 1941.
8. Garnick, M. B. Hormonal therapy in the management of prostate cancer: from Huggins to the present. Urology, 49 (3A Suppl.): 5-15, 1997.
9. Janne, O. A., Palvimo, J. J., Kallio, P., and Mehto, M. Androgen receptor and mechanism of androgen action. Ann. Med., 25: 83-89, 1993.
10. Jenster, G., van der Korput, H. A., van Vroonhoven, C., van der Kwast, T. H., Trapman, J., and Brinkmann, A. O. Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol. Endocrinol., 5: 1396-1404, 1991.
11. McPhaul, M. J. Molecular defects of the androgen receptor. J. Steroid Biochem. Mol. Biol., 69: 315-322, 1999.
12. Edwards, A., Hammond, H. A., Jin, L., Caskey, C. T., and Chakraborty, R. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics, 12: 241-253, 1992.
13. Sleddens, H. F., Oostra, B. A., Brinkmann, A. O., and Trapman, J. Trinucleotide (GGN) repeat polymorphism in the human androgen receptor (AR) gene. Hum. Mol. Genet., 2: 493, 1993.
14. Riegman, P. H., Vlietstra, R. J., van der Korput, J. A., Brinkmann, A. O., and Trapman, J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol. Endocrinol., 5: 1921-1930, 1991.
15. Lu, S., Tsai, S. Y., and Tsai, M. J. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI P16 genes. Cancer Res., 57: 4511-4516, 1997.
16. Miyashita, M. U. T., Ohtsuka, Y., Okamura-Oho, Y., Shikama, Y., and Yamada, M. Extended polyglutamine selectively interacts with caspase-8 and -10 in nuclear aggregates. Cell Death Differ., 8: 377-386, 2001.
17. Eder, I. E., Culig, Z., Ramoner, R., Thurnher, M., Putz, T., Nessler-Menardi, C., Tiefenthaler, M., Bartsch, G., and Klocker, H. Inhibition of LNCaP prostate cancer cells by means of androgen receptor antisense oligonucleotides. Cancer Gene Ther., 7: 997-1007, 2000.
18. Chamberlain, N. L., Driver, E. D., and Miesfeld, R. L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res., 22: 3181-3186, 1994.
19. n-expanded neuronopathies. Hum. Mol. Genet., 4: 523-527, 1995.
20. Irvine, R. A., Ma, H., Yu, M. C., Ross, R. K., Stallcup, M. R., and Coetzee, G. A. Inhibition of p160-mediated coactivation with increasing androgen receptor polyglutamine length. Hum. Mol. Genet., 9: 267-274, 2000.
21. Brooks, B. P., and Fischbeck, K. H. Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci., 18: 459-461, 1995.
22. Irvine, R. A., Yu, M. C., Ross, R. K., and Coetzee, G. A. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res., 55: 1937-1940, 1995.
23. Ingles, S. A., Ross, R. K., Yu, M. C., Irvine, R. A., La Pera, G., Haile, R. W., and Coetzee, G. A. Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor. J. Natl. Cancer Inst. (Bethesda), 89: 166-170, 1997.
24. Stanford, J. L., Just, J. J., Gibbs, M., Wicklund, K. G., Neal, C. L., Blumenstein, B. A., and Ostrander, E. A. Polymorphic repeats in the androgen receptor gene: molecular markers of prostate cancer risk. Cancer Res., 57: 1194-1198. 1997.
25. Giovannucci, E., Stampfer, M. J., Krithivas, K., Brown, M., Brufsky, A., Talcott, J., Hennekens, C. H., and Kantoff, P. W. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA. 94: 3320-3323, 1997.
26. Hsing, A. W., Gao, Y-T., Wu, G., Wang, X., Deng, J., Chen, Y-L., Sesterhenn, I. A., Mostofi, F. K., Benichou, J., and Chang, C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res., 60: 5111-5116, 2000.
27. Xue, W., Irvine, R. A., Yu, M. C., Ross, R. K., Coetzee, G. A., and Ingles, S. A. Susceptibility to prostate cancer: interaction between genotypes at the androgen receptor and prostate-specific antigen loci. Cancer Res., 60: 839-841, 2000.
28. Edwards, S. M., Badzioch, M. D., Minter, R., Hamoudi, R., Collins, N., Ardern-Jones, A., Dowe, A., Osborne, S., Kelly, J., Shearer, R., Easton, D. F., Saunders, G. F., Dearnaley, D. P., and Eeles, R. A. Androgen receptor polymorphisms: association with prostate cancer risk, relapse and overall survival. Int. J. Cancer, 84: 458-465, 1999.
29. Bratt, O., Borg, A., Kristoffersson, U., Lundgren, R., Zhang, Q-X., and Olsson, H. CAG repeat length in the androgen receptor gene is related to age at diagnosis of prostate cancer and response to endocrine therapy, but not to prostate cancer risk. Br. J. Cancer, 81: 672-676, 1999.
30. Correa-Cerro, L., Wohr, G., Haussler, J., Berthon, P., Drelon, E., Mangin, P., Fournier, G., Cussenot, O., Kraus, P., Just, W., Paiss, T., Cantu, J. M., and Vogel, W. (CAG)nCAA and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population. Eur. J. Hum. Genet., 7: 357-362, 1999.
31. Miller, E. A., Stanford, J. L., Hsu, L., Noonan, E., and Ostrander, E. A. Polymorphic repeats in the androgen receptor gene in high-risk sibships. Prostate, 48: 200-205, 2001.
32. Latil, A. G., Azzouzi, R., Cancel, G. S., Guillaume, E. C., Cochan-Priollet, B., Berthon, P. L., and Cussenot, O. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer (Phila.), 92: 1130-1137. 2001.
33. Beilin, J., Harewood, L., Frydenberg, M., Mameghan, H., Martyres, R. F., Farish, S. J., Yue, C., Deam, D. R., Byron, K. A., and Zajac, J. D. A case-control study of the androgen receptor gene CAG repeat polymorphism in Australian prostate carcinoma subjects. Cancer (Phila.), 92: 941-949, 2001.
34. Platz, E. A., Giovannucci, E., Dahl, D. M., Krithivas, K., Hennekens, C. H., Brown, M., Stampfer, M. J., and Kantoff, P. W. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomark. Prev., 7: 379-384, 1998.
35. Jenster, G., de Ruiter, P. E., van der Korput, H. A., Kuiper, G. G., Trapman, J., and Brinkmann, A. O. Changes in the abundance of androgen receptor isotypes: effects of ligand treatment, glutamine-stretch variation, and mutation of putative phosphorylation sites. Biochemistry, 33: 14064-14072, 1994.
36. Gao, T., Marcelli, M., and McPhaul, M. J. Transcriptional activation and transient expression of the human androgen receptor. J. Steroid Biochem. Mol. Biol., 59: 9-20, 1996.
37. Omenn, G. S. A double-blind randomized trial with β-carotene and retinol in persons at high risk of lung cancer due to occupational asbestos exposures and/or cigarette smoking. Public Health Rev., 16: 99-125, 1988.
38. Hardy, D. O., Scher, H. I., Bogenreider, T., Sabbatini, P., Zhang, Z. F., Nanus, D. M., and Catterall, J. F. Androgen receptor cag repeat lengths in prostate cancer: correlation with age of onset. J. Clin. Endocrinol. Metab., 81: 4400-4405, 1996.